SCHEMBL13701426

SCHEMBL13701426

COc1ccc(-c2nc(CCC(=O)c3ccccc3OC(C)C)co2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.43
S1PR3 Q99500 1/20 0.43
S1PR5 Q9H228 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.39
PTGS2 P35354 4/20 0.39
CTNNB1 P35222 2/20 0.39
WNT3A P56704 2/20 0.39
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
HTT P42858 2/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4273489 0.98 S1PR1 (0.41) S1PR1S1PR3S1PR5IRAK4PTGS2
SCHEMBL4276119 0.96 CTNNB1 (0.41) S1PR1S1PR3S1PR5IRAK4PTGS2
SCHEMBL19199080 0.94 S1PR1 (0.39) S1PR1S1PR3S1PR5IRAK4PTGS2
SCHEMBL4278967 0.94 SMN1; SMN2 (0.41) S1PR1S1PR3S1PR5IRAK4CTNNB1
SCHEMBL4275723 0.94 S1PR1 (0.38) S1PR1S1PR3S1PR5IRAK4PTGS2
SCHEMBL4270475 0.93 IDO1 (0.41) S1PR1S1PR3S1PR5IRAK4CTNNB1
SCHEMBL13701440 0.92 CTNNB1 (0.45) PTGS2CTNNB1WNT3AKDM4ESMN1; SMN2
SCHEMBL4271153 0.92 SMN1; SMN2 (0.39) S1PR1S1PR3S1PR5CTNNB1WNT3A
SCHEMBL4280751 0.92 S1PR1 (0.38) S1PR1S1PR3S1PR5PTGS2CTNNB1
SCHEMBL4277065 0.91 KDM4E (0.42) S1PR1S1PR3S1PR5KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A S1PR1 964/4885S1PR3 1212/4885S1PR5 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.